Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBD98-M for induction of remission in mild to moderate ulcerative colitis
2015-001022-42Phase 2Completed
- Sponsor
- Holy Stone Healthcare Co., Ltd.
- Start
- Mar 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Non-biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
A Phase 2 trial of mesalamine + sodium hyaluronate in autoimmune colitis, sponsored by Holy Stone Healthcare Co., Ltd.. Started Mar 2019; status: completed.
02
Drugs
mesalamine + sodium hyaluronate
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on 2015-001022-42.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-001022-42.